These findings expose the clinical relevance of deregulated Cer and HexCer biosynthesis pathways in CLL progression and suggest a combined influence of the UGT2B17 metabolic pathway and the enzymes involved in the sphingolipid synthesis pathways such as UGCG. This evidence concerns the gene UGT2B17 and B-cell chronic lymphocytic leukemia.